Chest
-
Respiratory Infections PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Vancomycin is standard of care for the treatment of methicillin-resistant Staphylococcus aureus infection (MRSA). Conventional dosing strategies are intermittent dosing with assessment of therapeutic level. First trough level is obtained before the 4th dose. It often results in readjusting dose and frequency of vancomycin to obtain adequate levels. As the mortality rate for MRSA bacteremia remains high 23.4%, no study has looked at continuous infusion vancomycin (CIV) since the IDSA guidelines in 2009 changing therapeutic level interpretation. We conducted a retrospective review at our academic center to review steady state levels, complications and morbidity. ⋯ The following authors have nothing to disclose: Syed Masood, Christopher Droege, Renee Hebbeler-ClarkNo Product/Research Disclosure Information.
-
Congenital Disorder Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Common manifestations of Alpha-1 antitrypsin (AAT) deficiency include panacinar emphysema, bronchiectasis, and cirrhosis. Rarely association of inflammatory bowel disease, vasculitis, psoriasis, urticaria, and angioedema have been described. Here, we present an unusual case with necrotizing panniculitis and pulmonary ground glass opacities (GGO) on chest CT. ⋯ Rajiv Dhand: Consultant fee, speaker bureau, advisory committee, etc.: GSK, Grant monies (from industry related sources): International Physician coordinator for astra-zeneca multicenter study; Bayer site PI, GSK site PI, Consultant fee, speaker bureau, advisory committee, etc.: Mylan pharmaceuticals; Cardeas Pharma The following authors have nothing to disclose: Kashif Aslam, Naveed Sheikh, Syed Mudassar Naqshbandi, Amnah AndrabiNo Product/Research Disclosure Information.
-
Pediatric PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Congenital pulmonary malformations like congenital cystic adenomatoid malformation and bronchogenic cysts are rare but potentially life-threatening anomalies. It frequently present with neonatal respiratory distress and require prompt diagnosis and treatment. Physical signs are nonspecific: grunting, tachypnea, retractions, cyanosis, pneumothorax. ⋯ The following authors have nothing to disclose: Manuela Cucerea, Marta Simon, Raluca Marian, Luminita ZahiuNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: In this retrospective study, we compare the meterological parameters between the patients who had risk factors and idiopatic pulmonary embolism (PE) patients. We looked for seasonal variations in the incidence of idiopathic PE and a relationship with atmospheric pressure, humidity, or temperature. ⋯ The following authors have nothing to disclose: Tuba Inal, Ceyda Anar, Ipek Unsal, Gülru Polat, Hüseyin HalilçolarNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The ILLUMINATE study evaluated the superiority of once-daily QVA149 110/50μg, a dual bronchodilator combining the LABA indacaterol and LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500μg (SFC), in terms of efficacy, safety and tolerability in patients with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 versus SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment. ⋯ Karen Mezzi: Employee: Novartis Employee John Pallante: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.